{"filings":[{"id":2271156,"accession_number":"0001161697-26-000200","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2026-08-14T20:01:58+00:00","items":["5.03","9.01"],"status":"ready","headline":"KORU Medical amends bylaws to give shareholders exclusive director-removal authority","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board unanimously adopted Amendment No. 1 to Section 3.05 of Amended and Restated By-laws effective August 13, 2026.","Amendment vests director removal exclusively in affirmative vote of shareholders holding a majority of outstanding shares, per Delaware law.","Board states it has not voted, and has no intention or agreement, to remove any director.","Amendment filed as Exhibit 3.1; no financial or operational impact disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2078716,"accession_number":"0001161697-26-000188","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2026-08-05T20:04:32+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical Q2 revenue $12.0M (+18% YoY), net income $0.25M, raises gross margin guidance to 62-64%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $12.0M (+18% YoY); gross profit $7.8M (+20%); gross margin 65.1% vs 63.5% prior year.","Net income $0.25M vs net loss ($0.2M) prior year; adjusted EBITDA $0.9M vs $0.3M.","Updated FY2026 guidance: revenue $47.5-$48.5M (15-18% growth), gross margin 62-64%, positive adjusted EBITDA, year-end cash >$7.5M.","Acquired connected monitoring technology asset; withdrew 510(k) for FreedomEDGE with Phesgo in U.S., shifting oncology strategy to higher volume molecules.","Entered multi-year supply agreement; cash $8.3M at quarter end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1362478,"accession_number":"0001161697-26-000139","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2026-06-30T20:57:42+00:00","items":["1.01","9.01"],"status":"ready","headline":"KORU Medical amends manufacturing agreement with Command; extends term to 2031, adds second site requirement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment extends initial term to Dec 31, 2031, with auto-renewal unless 180-day non-renewal notice given.","Command must obtain and qualify a second manufacturing site by Dec 31, 2027; KORU can terminate if not cured in 30 days.","Pricing and payment terms modified, including annual price adjustments and pass-through cost savings.","Command becomes exclusive manufacturer for a limited set of products; non-compete provision removed.","IP ownership clarified and assignment rights made mutual between the parties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":582039,"accession_number":"0001161697-26-000128","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2026-05-21T20:11:32+00:00","items":["5.07"],"status":"ready","headline":"KORU Medical shareholders approve all proposals at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected with over 97% of votes cast.","Shareholders approved amendment to 2024 Omnibus Equity Incentive Plan to increase share pool.","Advisory say-on-pay vote passed with ~99.6% of votes cast.","Advisory vote on frequency set at every one year (24.9M votes for 1-year).","Ratification of Cherry Bekaert as auditor for FY 2026 approved with ~99.9% of votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98378,"accession_number":"0001161697-26-000107","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical Q1 revenue $11.8M (+22% YoY); net loss improves to $0.8M; FY guidance reiterated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $11.8M, up 22% YoY; domestic core +11.7%, international core +35.2%, pharma services +166%.","Gross profit $7.2M (+20% YoY); gross margin 61.5% vs 62.8% on tariff costs and production timing.","Net loss improved 31% to $0.8M ($0.02 diluted EPS) from $1.2M ($0.03) in prior year.","Cash $8.8M; cash usage $0.1M in Q1. Reiterates FY2026 revenue $47.5-50.0M, positive adjusted EBITDA & cash flow.","Submitted 510(k) for Freedom Infusion System with deferoxamine; two pharma collaborations advanced to Phase III."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":11764624.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98377,"accession_number":"0001161697-26-000086","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"KORU Medical amends HSBC credit facility, extends maturities and lowers rate floor","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment extends $5M revolver maturity from Dec 31, 2026 to Mar 30, 2028.","Term loan interest-only period extended to Jun 30, 2027, with possible further extension to Dec 31, 2027 upon EBITDA milestones.","Term loan maturity extended to Dec 1, 2029; interest rate floor reduced to 5.50% from 6.50%.","Adjusted quick ratio covenant removed; replaced by 12-month liquidity covenant when drawn or positive trailing 3-month Adjusted EBITDA.","Company has not drawn on the $10M total facility and has no obligation to do so."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113802,"accession_number":"0001161697-26-000055","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO Linda Tharby to retire June 2026; Adam Kalbermatten named successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tharby retires as CEO effective June 30, 2026; will serve as advisory employee through Dec 31, 2026.","Kalbermatten appointed President March 15, 2026, and becomes CEO July 1, 2026.","Kalbermatten's base salary: $450K through June, then $525K; 2026 bonus target 80%; LTI target $1.25M.","One-time PSU award of $1.25M to Kalbermatten effective July 1, 2026 with performance goals (75% revenue growth, 25% market cap).","Tharby's equity: some PSUs/RSUs continue vesting through Dec 31, 2026; all remaining unvested awards forfeited thereafter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113801,"accession_number":"0001161697-26-000051","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical reports 22% FY2025 revenue growth; positive adjusted EBITDA; initiates FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net revenue $10.9M (+23% YoY); FY2025 net revenue $41.1M (+22% YoY).","International Core revenue grew 80% in FY2025; Domestic Core grew 11%.","FY2025 net loss narrowed 57% to $2.6M ($0.06 loss per share); positive adjusted EBITDA of $0.6M.","Cash and cash equivalents $8.9M at Dec 31, 2025; used only $0.7M cash in FY2025.","FY2026 guidance: net revenue $47.5–$50.0M (15–22% growth); positive adjusted EBITDA and positive cash flow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113800,"accession_number":"0001161697-26-000038","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"KORU Medical amends bylaws to enhance stockholder nomination procedures","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board unanimously adopted amended bylaws effective Feb 5, 2026.","Enhances procedural mechanics and disclosure for stockholder nominations and proposals.","Requires compliance with universal proxy Rule 14a-19 and additional disclosures from nominating stockholders.","Changes advance notice deadline for director nominations when board size increases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113799,"accession_number":"0001161697-26-000027","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical prelim Q4 revenue $10.9M (+23% YoY); FY revenue $41.1M (+22% YoY); positive op cash flow","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2025 net revenue $10.9M, up 23% YoY; full year net revenue $41.1M, up 22% YoY.","Ending cash balance $8.9M; positive cash flow from operations in Q4 and for full year.","Submitted 510(k) for Freedom Infusion System for use with Phesgo, expanding into oncology.","Company plans to release final 2025 results and 2026 guidance in early March 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":41127366.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130210,"accession_number":"0001161697-25-000426","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"KORU Medical restates manufacturing/supply pact with Command Medical through 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended and Restated Manufacturing and Supply Agreement with Command Medical Products, effective Jan 1, 2024.","Agreement expires Dec 31, 2026, with automatic one-year renewals unless either party opts out.","Covers manufacturing of subassemblies, needle sets, and tubing per KORU specifications and purchase orders.","Includes pricing, payment, rebates, purchase commitments, warranty, IP, and confidentiality terms.","Either party may terminate on uncured material breach (45-day cure) or bankruptcy/insolvency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130209,"accession_number":"0001161697-25-000371","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical Q3 revenue $10.4M (+27% YoY), raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net revenues $10.4M, up 27% YoY; core business (domestic + international) $9.8M, up 30%.","Net loss narrowed 51% to $0.8M; positive adjusted EBITDA of $0.09M vs. $(0.4M) prior year.","International core revenue surged 229.6% to $3.7M; domestic core declined 5.0%.","Raising FY2025 revenue guidance to $40.5-41.0M (from $39.5-40.5M); gross margin guidance reiterated at 61-63%.","Ending cash balance $8.5M; generated $0.4M cash in Q3; reiterating positive full-year cash flow."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":30232038.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146769,"accession_number":"0001161697-25-000216","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical Q2 revenue up 21% to record $10.2M; raises FY 2025 revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 net revenue of $10.2 million, +21% YoY; Core revenue $9.3M (+19%), PST $0.9M (+42%).","Adjusted EBITDA positive $0.3M vs ($0.4M) in prior year; net loss narrowed to $0.2M from $1.3M.","Raises FY 2025 revenue guidance to $39.5-$40.5M (prev. $38.5-$39.5M); gross margin guidance 61%-63% reaffirmed.","Cash balance $8.1M at Q2-end; reiterated positive operating cash flow for FY 2025.","Adam Kalbermatten named Chief Commercial Officer; FDA 510(k) submitted for a rare disease biologic drug."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":19829875.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165198,"accession_number":"0001161697-25-000173","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"KORU Medical Systems shareholders elect all director nominees at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven nominees elected; votes 'for' ranged from 23.5M to 23.9M of 23.95M cast (excl. broker non-votes).","Advisory vote on executive compensation passed: 23.2M for, 0.7M against, 81.6K abstain.","Ratification of Cherry Bekaert LLP as independent auditor for 2025: 36.9M for, 9.6K against.","Total shares voted: 36,949,703; broker non-votes were 12,997,325 on director and compensation proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165197,"accession_number":"0001161697-25-000168","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical reports record Q1 revenue of $9.6M, up 18% YoY; raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Core revenue (Domestic + International) grew 21% YoY to $9.4M; International up 35.6%.","Gross margin improved 50 bps to 62.8%; gross profit $6.0M, up 19%.","Net loss narrowed; adjusted EBITDA improved to ($0.2M) from ($0.9M) prior year.","FY2025 revenue guidance raised to $38.5-39.5M from $38-39M; gross margin guidance reiterated at 61-63%.","Plans to submit two drugs for FDA 510(k) clearance with Freedom Infusion System by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":9635075.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165196,"accession_number":"0001161697-25-000142","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["5.02","7.01"],"status":"ready","headline":"KORU Medical CCO resigns; FY2025 revenue guidance reiterated at $38-39M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kenneth Miller resigned as Chief Commercial Officer effective April 3, 2025, to become CEO at a non-competing firm.","Rob Cannon (VP of Sales, North America) will lead Core commercial operations until a permanent CCO is named.","Company retained an executive search firm to find a new CCO.","KORU Medical reaffirmed FY2025 revenue guidance of $38.0-$39.0 million, unchanged from March 12 call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165195,"accession_number":"0001161697-25-000140","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"KORU Medical amends loan agreement, extends credit facility maturity to Dec 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment extends $5M revolving credit facility maturity to Dec 31, 2026; term loan interest-only period to Oct 1, 2026.","Adjusted Quick Ratio covenant reduced from 1.50:1.00 to 1.25:1.00; company has not drawn on facility.","Amendment with HSBC Ventures USA Inc. effective March 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182879,"accession_number":"0001161697-25-000099","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical reports record Q4 revenue of $8.8M (+23% YoY); issues 2025 guidance $38-39M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net revenue $8.8M (+23% YoY); full year $33.6M (+18% YoY).","Q4 gross margin 62.9% (+260 bps); full year 63.4% (+480 bps).","Net loss improved to $1.6M (Q4) and $6.1M (full year); adjusted EBITDA loss narrowed.","Cash $9.6M at Dec 31; Q4 cash flow positive $0.8M; 2025 guidance: revenue $38-39M, gross margin 61-63%, operational cash flow positive.","Novel Therapies segment renamed Pharma Services and Clinical Trials (PST), effective Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182878,"accession_number":"0001161697-25-000050","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"KORU Medical reports record Q4 revenue $8.9M (+23% YoY); positive cash flow in Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary full-year 2024 net revenue of $33.7M, up 18% YoY; Q4 revenue $8.9M, up 23% YoY.","Ending cash balance $9.6M; Q4 generated positive cash flow of $0.8M.","Full-year cash burn $1.9M, a 67% improvement over prior year.","CEO cites U.S. market share gains, international expansion, and progress on new drug therapy labeling."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":33646463.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199463,"accession_number":"0001161697-24-000440","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical Q3 revenue $8.2M (+17% YoY); raises FY 2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net revenue $8.2M, up 17% YoY; gross margin 63.4%, up 140 bps from 62.0%.","Core revenue $7.6M (+11% YoY); novel therapies $0.6M (+276% YoY).","Net loss $1.6M ($0.03 diluted EPS); adjusted EBITDA loss $0.4M.","Raises FY 2024 revenue guidance to $32.75-33.25M (15-17% growth) from $32.0-32.5M.","Raises FY 2024 gross margin guidance to 62-63%; year-end cash guidance >$8.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":24807864.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215499,"accession_number":"0001161697-24-000365","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2024-08-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"KORU Medical Systems adopts LTIP; grants up to 434,489 PSUs plus RSUs and options to execs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LTIP approved; equity awards granted to CEO Tharby (63,872 RSUs, 127,660 PSUs, 140,950 options) and other named execs.","PSUs vest based on FY2026 revenue achievement (0%-150% of target) with stock price modifier (0.5x-1.5x); max shares 434,489.","RSUs and options vest over 4 years; option exercise price $2.33 per share.","Kenneth Miller (CCO) gets base salary increase to $385,000 and bonus potential up to 60% of base."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215498,"accession_number":"0001161697-24-000335","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical Q2 revenue record $8.4M, up 22%; raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net revenues of $8.4M, a 22% YoY increase; core business grew 20% driven by SCIg market growth and share gains.","Gross margin expanded to 65% from 56.1% YoY, a 890bps improvement; gross profit up 41% to $5.5M.","Net loss improved to $1.0M ($0.02 per share) from $2.5M loss ($0.05 per share) in Q2 2023; adjusted EBITDA loss narrowed to $0.4M.","Raised FY2024 revenue guidance to $32.0-$32.5M (12-14% growth) and gross margin guidance to 61-62%.","Cash balance $10.5M; quarterly cash usage $0.3M; reaffirmed cash flow breakeven in Q4 2024 and positive cash in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":16627887.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215497,"accession_number":"0001161697-24-000314","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2024-07-24T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"KORU Medical appoints Christopher Pazdan as COO, eliminates CTO role held by Brian Case","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher Pazdan appointed Chief Operating Officer, effective July 18, 2024, from SVP Operations.","Brian Case's position as Chief Technology Officer eliminated, termination effective September 16, 2024.","Pazdan's base salary set at $350,000, annual bonus up to 50% of base salary; severance includes 12 months base salary plus health premiums.","Pazdan joined KORU in 2021, has over 20 years experience in medical technology QA/regulatory affairs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234836,"accession_number":"0001161697-24-000250","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Koru Medical dismisses MMQ as auditor, engages Cherry Bekaert","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee dismissed McGrail Merkel Quinn & Associates (MMQ) effective June 3, 2024.","Engaged Cherry Bekaert LLP as independent auditor for fiscal year ending December 31, 2024.","MMQ reports for FY 2023 and 2022 had no adverse opinion, disclaimer, or modifications.","No disagreements or reportable events occurred with MMQ during the past two years or interim period.","MMQ provided a letter to the SEC agreeing with the company's disclosures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234835,"accession_number":"0001161697-24-000230","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Koru Medical Systems reports 2024 annual meeting results; all proposals passed","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected all 7 director nominees: Fletcher, Cascella, French, Manko, Matin, Tharby, Wholihan.","Advisory compensation vote approved: 26.4M for, 0.5M against, 0.2M abstain.","Ratified McGrail Merkel Quinn as independent auditor for 2024 (38.3M for, 11.5K against).","Approved 2024 Omnibus Equity Incentive Plan (26.1M for, 0.8M against, 0.2M abstain)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234834,"accession_number":"0001161697-24-000225","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical Q1 revenue up 11% to $8.2M; gross margin expands 620bps to 62.3%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues of $8.2M, +10.9% YoY; Core business grew 13.6%, driven by 63% International increase.","Gross margin 62.3% vs 56.1% YoY, aided by outsourced manufacturing and US site consolidation.","Net loss narrowed to $1.9M ($0.04/share) from $2.4M; Adj EBITDA loss improved to $0.9M.","Reaffirmed FY2024 revenue guidance of $31.2-32.2M (10-13% growth); gross margin 59-61% expected.","Added a novel oncology therapy collaboration, bringing total to 16, with 3 YTD."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":8197798.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234833,"accession_number":"0001161697-24-000196","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2024-04-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"KORU Medical wins EU notified body appeal, CE certification continues uninterrupted","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["BSI had recommended against continued certification after March 2024 audit nonconformance.","Appeal upheld April 8, 2024; no suspension or interruption of EU product sales.","Products remain certified, marketed, and sold in EU; proceeds through routine BSI assessment.","CEO Linda Tharby cites swift team response and positive BSI interaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252685,"accession_number":"0001161697-24-000140","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["1.01","2.02","2.03","3.02","9.01"],"status":"ready","headline":"KORU Medical reports Q4 rev $7.2M, FY net loss $13.7M; guides 2024 rev $31.2-32.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net revenues $7.2M (-2% YoY); gross margin improved to 60.3% (+470bps).","Full year net loss $13.7M ($0.30/sh) includes $6M non-cash tax valuation allowance; Adjusted EBITDA ($6.0M) vs ($6.1M) prior year.","Full year 2024 revenue guidance $31.2-32.2M (10-13% growth); gross margin 59-61%; cash flow breakeven in Q4 2024.","Entered $10M credit facility with HSBC ($5M revolver + $5M term loan; undrawn); warrant for 76,104 shares at $2.12.","EU notified body BSI recommended against continued certification; appeal filed; mgmt expects minimal revenue impact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270167,"accession_number":"0001161697-23-000567","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","5.02","8.01","9.01"],"status":"ready","headline":"KORU Medical Q3 revenue down 9.8% YoY; cuts full-year guidance to $28.0-$28.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net revenue $7.0M (-9.8% YoY); net loss $1.4M ($0.03/share) vs $1.2M loss prior year.","Full-year 2023 revenue guidance cut to $28.0-$28.5M from $31.0-$32.5M; gross margin reaffirmed 58%-60%.","FDA cleared FREEDOM60 Infusion System for use with Hizentra 50 mL prefilled syringes; first such clearance.","Appointed Ken Miller as CCO effective Nov 6; base salary $360K, bonus up to 50%, and 400,000 stock options."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":21331734.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270166,"accession_number":"0001161697-23-000522","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2023-10-04T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"KORU Medical appoints Edward Wholihan to Board of Directors effective September 28, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Edward Wholihan appointed to fill Board vacancy on Sept 28, 2023; brings over 25 years CFO experience in life sciences and healthcare.","Wholihan previously consulted for KORU Medical from Jan to June 2023, receiving $131,250 in consulting fees.","As non-employee director, Wholihan will receive compensation per the Company's Non-Employee Director Compensation Plan.","Wholihan's prior CFO roles include Rarebreed Veterinary Partners, Allena Pharmaceuticals, and Medical Specialties Distributors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287148,"accession_number":"0001161697-23-000441","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical Q2 revenue $6.9M (+6% YoY); cuts FY2023 revenue guidance to $31.0-32.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net revenue $6.9M (+6% YoY); Domestic Core +8%, International Core +17%.","Net loss $2.5M ($0.05/sh) improved from $2.9M loss ($0.07/sh) prior year; gross margin 56.1%.","Cuts FY2023 revenue guidance to $31.0-32.5M (11-17% growth) from prior $32.5-33.5M (17-20% growth).","Appoints Tom Adams as CFO; submitted 510(k) for FREEDOM60 with Hizentra prefilled syringes.","Reaffirms FY2023 gross margin 58-60% and year-end cash >$10.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":14328536.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287147,"accession_number":"0001161697-23-000429","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"KORU Medical Q2 prelim revenue $6.9M (+6% YoY); cuts FY2023 guidance to $31-32.5M; CFO resigns","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2023 preliminary net revenue ~$6.9M, up 6% YoY; Domestic Core +8%, International Core +17%, Novel Therapies -28%.","FY2023 revenue guidance lowered to $31-32.5M (11-17% growth) due to weaker U.S. SCIg market and Novel Therapies timing.","Cash $11.7M at June 30; reaffirms FY2023 gross margin 58-60% and year-end cash over $10M.","CFO Andy LaFrence resigned July 27 for personal/family reasons; Thomas Adams (VP FP&A, interim CFO) appointed CFO effective Aug 1.","Adams gets base salary $325k, 50% bonus target, nonqualified options for 100k shares at $2.54, four-year vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":14328536.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307244,"accession_number":"0001161697-23-000378","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2023-06-27T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"KORU Medical appoints Andrew LaFrence as CFO, effective July 10, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew LaFrence brings 39 years of finance/accounting experience; previously CFO at Vyant Bio and Surmodics, 26 years at KPMG.","Base salary of $350k per year; eligible for annual cash bonus up to 50% of base salary.","Inducement option to purchase 300,000 shares of common stock, vesting 25% annually over 4 years.","Tom Adams, interim CFO, will continue as VP of Financial Planning and Analysis.","LaFrence will support the Vision 2026 growth strategy and scaling of the business."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307243,"accession_number":"0001161697-23-000302","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2023-05-17T23:59:59+00:00","items":["1.01","5.02","3.03","5.03","5.07","8.01","9.01"],"status":"ready","headline":"KORU Medical reincorporates in Delaware, files $71.25M shelf registration","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reincorporation effective May 16, 2023; each NY share converted to one DE share; business unchanged.","Same board of directors and executive officers; committees unchanged.","Filed new universal shelf S-3 for up to $71.25M; replaces expiring 2020 shelf, provides capital flexibility.","Annual meeting: all director nominees elected, advisory say-on-pay approved, auditor ratified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307242,"accession_number":"0001161697-23-000280","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical Q1 revenue $7.4M (+18% YoY); reaffirms FY2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net revenue $7.4M, up 18% YoY; net loss $2.4M ($0.05 diluted) vs $2.5M loss prior year.","U.S. Core revenue $5.7M (+15%), International Core $1.1M (+23%), Novel Therapies $0.6M (+62%).","Gross margin 56.1% (down from 58%), but reaffirms FY margin 58-60% and exit at 60-62%.","Reaffirms FY2023 revenue guidance $32.5-33.5M (17-20% growth); cash >$10M year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":7392605.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326280,"accession_number":"0001161697-23-000156","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical reports 19% revenue growth in 2022, guides 17-20% growth for 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $7.34M (+13.2% YoY); FY2022 revenue $27.9M (+18.8% YoY).","FY2022 net loss $8.6M ($0.19 loss per share) vs $4.6M loss in 2021.","Novel Therapies revenue grew 329.8% to $2.5M; Core business grew 11%.","Cash $17.4M at year-end; 2023 guidance: revenue $32.5-$33.5M (17-20% growth), gross margins 58-60%, cash >$10M.","Expects 6 new Novel Therapies collaborations and two 510(k) filings in H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343996,"accession_number":"0001161697-22-000537","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical Q3 revenue up 28.5% to $7.8M; raises FY2022 guidance to $27.5-28.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $7.76M (+28.5% YoY); domestic core +16.2%, international core +46.8%, novel therapies +251.9%.","GAAP net loss $1.2M ($0.03 diluted EPS) vs $1.1M loss ($0.02) in Q3 2021; gross margin 55.7% vs 57.9%.","Full-year 2022 revenue guidance raised to $27.5-28.0M (from $27.0-27.5M); opex guidance lowered to $26.5-27.0M.","Cash $16.4M; management confirms year-end cash minimum of $16.0M.","Novel therapies pipeline: four new Phase II trials, one drug progressed to Phase III."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":20551356.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":360497,"accession_number":"0001161697-22-000375","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical Q2 net sales up 18.4% to $6.5M; raises FY revenue guidance but lowers margin forecast","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $6.5M (+18.4% YoY) driven by novel therapies (NRE milestone) and core growth; backorders $0.3M.","GAAP net loss $2.9M (EPS -$0.07) vs $1.1M loss a year ago; adjusted EPS -$0.06.","Raises FY 2022 revenue guidance to $27.0–27.5M (from $26.5–27.0M); lowers gross margin guidance to 55–60% (from 60%).","Manufacturing transfer to contract manufacturer delayed to Q1 2023 (from Q4 2022); cash $18.3M at quarter end.","Expanded novel therapies pipeline with two new biopharmaceutical agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":12790958.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":360496,"accession_number":"0001161697-22-000345","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2022-07-06T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"KORU Medical modifies $3.5M credit line; extends maturity to June 2023, changes interest rate","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered Loan Modification Extension Agreement with KeyBank National Association on June 29, 2022.","Maturity of $3.5M revolving credit line extended to June 1, 2023.","Interest rate changed from Prime minus 1.50% to Prime plus 0%.","Released prior security interest in equipment, inventory, and accounts; replaced with pledge on certain bank accounts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379553,"accession_number":"0001161697-22-000325","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2022-06-28T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"KORU Medical Systems completes legal name change from Repro Med Systems Inc.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name changed to KORU Medical Systems, Inc. effective June 22, 2022 after shareholder approval on May 6, 2022.","Ticker symbol KRMD and Nasdaq listing unchanged; outstanding stock certificates remain valid and need not be exchanged.","Company had been operating under the DBA name KORU Medical Systems since October 24, 2019."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379556,"accession_number":"0001161697-22-000259","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2022-05-18T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Repro Med CFO Karen Fisher to resign June 30, 2022; Tom Adams named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Karen Fisher resigns effective June 30, 2022; no disagreements with company.","Transition Agreement includes severance per existing employment agreement and $60,000 payment.","Tom Adams, VP of Financial Planning & Analysis since Nov 2021, will serve as interim CFO from July 1.","Adams has 20+ years med-tech/pharma finance experience, previously at Integra Life Sciences and Pfizer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379555,"accession_number":"0001161697-22-000232","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shareholders approve name change to Koru Medical Systems, Inc. and Delaware reincorporation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 6 proposals at 2022 annual meeting passed by wide margins.","Name change to 'Koru Medical Systems, Inc.' approved with 38.2M shares for, 0.1M against.","Merger into Delaware subsidiary for reincorporation approved (30.8M for).","Seven director nominees elected; R. John Fletcher received 29.8M votes.","Advisory say-on-pay approved (28.3M for); auditor McGrail Merkel Quinn ratified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379554,"accession_number":"0001161697-22-000215","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical Q1 net sales up 15% to $6.2M, net loss widens to $2.5M, raises FY22 revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $6.24M (+15% YoY); domestic core up 13.2%, novel therapies $0.36M (including NRE).","GAAP net loss $2.5M (-$0.06 EPS) vs $1.3M loss (-$0.03 EPS) prior year; adjusted EPS -$0.05.","Gross margin 58.0% (-150bps) on higher raw material/labor costs; operating expenses $6.7M (+24% YoY).","Raises FY22 revenue guidance to $26.5-$27.0M (prev $26.0-$27.0M); reaffirms 60% gross margin exit run rate."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":6244330.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":397752,"accession_number":"0001161697-22-000132","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2022-03-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical Q4 revenue up 60% to $6.5M, but full-year net loss widens to $4.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net revenues $6.5M (+60% YoY); adjusted growth 27.6% excluding prior-year inventory stocking.","Full-year net loss $4.6M ($0.10 per share) vs $1.2M loss in 2020; adjusted EBITDA ($1.8M) vs $3.7M.","Ended 2021 with $25.3M cash; expects FY2022 revenue of $26-27M with gross margin exit run rate 60%.","Expanded label indications with three 510(k) clearances; announced strategic plan targeting $60M revenue by 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":416736,"accession_number":"0001161697-21-000572","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2021-12-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"KORU Medical expects FY2021 revenue $23.0M-$23.2M; Q4 to show sequential growth","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q4 2021 expected to be the fourth consecutive quarter of positive sequential revenue growth.","Full year 2021 revenue guidance of $23.0 million to $23.2 million.","Domestic SCIg market expected to recover to mid-to-high single digits in 2022.","Company expects its domestic SCIg revenue growth to be slightly ahead of the market recovery."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":416735,"accession_number":"0001161697-21-000567","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2021-12-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"KORU Medical to unveil updated strategic plan at investor day on Dec 9, 2021","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Management to present updated strategic plan via webcast on Thursday, Dec 9, 2021 at 10:00 AM EST.","Webcast accessible live and archived on KORU Medical's website for six months.","No specific details of the strategic plan were disclosed in the filing or press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":416734,"accession_number":"0001161697-21-000521","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical Q3 net loss $1.1M; revenue $6.0M, 9% sequential growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $6.0M, 9% sequential growth; adjusted net revenue up 9% YoY excluding prior year inventory stocking.","Net loss $1.1M ($0.02 per share) vs net income $0.2M ($0.01) in Q3 2020.","Gross margin 57.9%, down from 64.8% due to manufacturing transition delays and scrap reserve.","Received FDA 510(k) clearance for Hizentra 20ml prefilled syringe with Freedom Edge system.","Three leadership hires and strategic plan update scheduled for December 2, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":16999669.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":434306,"accession_number":"0001161697-21-000375","cik":704440,"company_name":"KORU Medical Systems, Inc.","ticker":"KRMD","form_type":"8-K","filed_at":"2021-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KORU Medical Q2 net revenue $5.5M; net loss $1.1M; sequential growth of 2%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue of $5.5 million, down 28.3% YoY but up 2% sequentially.","Gross margin 58.1%, down 5.6 ppts YoY due to lower volumes.","Net loss of $1.1 million ($0.03 diluted loss per share).","Non-GAAP adjusted EBITDA of $(0.3) million vs $1.8 million in Q2 2020.","Mid-single-digit growth in domestic immunoglobulin market and specialty pharmacy channel indicates market recovery."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":10959125.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":190621936.1666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}